Help us: Donate
Follow us on:



Scholar Rock

Organization Description

Unlike traditional approaches, Scholar Rock targets growth factors in their inactive precursor, or latent, forms to selectively regulate their activity in the microenvironment of cells and tissues. They have applied this extraordinary selectivity to a number of growth factors, including to transforming growth factor beta (TGFΞ²) which plays a key role in age-related inflammation and impairs tissue regeneration.

Directly in the context of aging, they are developing a drug to inhibit excessive TGFΞ² signalling to potentially suppress the development of fibrosis, the result of imperfect repair, in multiple organs. They are also actively developing other drugs that tackle signalling relating to cancer, spinal muscular atrophy, and iron-restricted anemias.